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Abstract
Serotonin has a particular place in the modulation of pain. Experimental studies
have described 5-HT1–7 receptors and their effects on facilitation or inhibition of
nociceptive input. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-
norepinephrine reuptake inhibitors showed efficient and safer than tricyclic anti-
depressants in neuropathic pain. Although there is evidence regarding the beneficial
impact of SSRIs in the multimodal acute pain management, studies are still
searching for the potentially favorable effect of these drugs in the prevention of
chronic postoperative pain. The scope of this chapter would be to update the
knowledge regarding serotonin involving in pain pathways and to highlight the
importance and contribution of serotonin reuptake inhibitors in the multimodal
pain management schemes.
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1. Introduction
Chronic pain is recognized today as a disease [1], affects almost 20% of the
population [2], and represents a significant cause of disability bringing along high
secondary social costs. The management of chronic pain involves pharmacological
and interventional tools and become a priority for healthcare systems. This chapter
aims to summarize the role of serotonin reuptake inhibitors (SRI) in the treatment
of chronic pain. SRI includes selective serotonin reuptake inhibitors (SSRI) and
serotonin-norepinephrine reuptake inhibitors (SNRI).
2. Chronic pain conditions
Defined as the pain that lasts more than 3 months, frequent after the disappear-
ance of the causal factor, chronic pain shows numerous risk factors (socio-
demographic, biological, clinical, and psychological). Thus, most affected are
females, older people, and people with low socio-economic level. A significant risk for
developing chronic pain is the pain itself (acute and chronic at other sites), and also
are incriminated the geographical background, occupational factors, and the history
of abuse and violence. Neuroimaging studies have already proved the changes in the
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brain with severe pain, reversible with proper treatment, and also suggested its
importance for preventing the chronicization of pain [3]. The treatment of chronic
pain is multi/interdisciplinary and multimodal, targeting different mechanisms of
pain. We summarized some critical pain syndromes, which benefit from the SRI
medication.
2.1 Diabetic neuropathy
Diabetes mellitus affects billions of people worldwide. The painful diabetic
neuropathy (PDPN) occurs in 20% of diabetes patients during the disease. Risk
factors include age, hypertension, obesity, alcohol abuse, and smoking.
Pathogenesis implies endoneurial microangiopathy and axonal loss, especially in
sensory nerves. Aldose reductase activation by increasing polyol flux and the depo-
sition of advanced glycated end-products are the primary determinants of PDPN.
Secondary ischemia leads to enhanced oxidative stress and high production of free
radicals, which leads to nerve damage [4].
Clinical PDPN may present as burning, stabbing, dull and aching, or sharp pain.
In some instances, allodynia (painful response to a normally non-noxious stimulus)
might accompany pain. PDPN is symptomatic mainly in the lower limbs and pro-
gresses proximally. Patients with PDPN show skin changes and loss of sensory that
could lead further to diabetic ulcers.
The medication of painful diabetic neuropathy includes duloxetine, venlafaxine,
tricyclic antidepressants (TAD), oxcarbazepine, and tapentadol. Overall, the quality
of life in patients with PDPN is poor [5].
2.2 Fibromyalgia
Fibromyalgia (FM) is a syndrome composed of widespread chronic pain, muscle
fatigue, and functional symptoms. It shows a genetic predisposition, but environ-
mental factors play a prominent place during the disease. FM pathogenesis involves
modified inflammatory response and oxidative stress [6].
Diagnosis is difficult because of the variety of clinical symptoms—75% of these
patients do not meet the inclusion criteria, thus often they lack the diagnosis.
Besides, these patients develop sleep disturbances and sexual dysfunction, altering
further the quality of life.
The current evidence suggest for FM management antidepressants, cardiovas-
cular exercise, and cognitive behavioral therapy [7]. Meta-analysis results agree that
the medication approved by FDA—milnacipran—and duloxetine are effective in
FM while there are concerns that the results showed only a moderate effect on pain
and sleep, and no impact on fatigue [8].
2.3 Tension-type headache
Tension-type headache (TTH) is a typical headache (up to 78%), caused by the
contractions of muscles of the scalp, neck, and jaw, and triggered mainly by stress
and emotional conflicts. It is described as a moderate pressure applied to the frontal
area, around the head or neck, and according to its frequency is classified as
infrequent, frequent, and chronic.
Chronic TTH results as a consequence of sensitization of the pain pathway due
to persistent pericranial myofascial nociceptive input. This TTH shows a frequency
of at least 15 days/month for at least 3 months. If nausea and vomiting are present,
exclude the diagnosis of TTH. Photophobia may occur in TTH.
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Treatment of the acute episodes of TTH includes nonsteroidal anti-
inflammatory drugs and acetaminophen, while their prevention associates pharma-
cologic and non-pharmacologic (physical and psychologic therapy) interventions.
Tricyclic antidepressants (amitriptyline) are the most studied drugs in TTH, but
new studies showed efficacy for other antidepressants including SRI—citalopram,
sertraline, venlafaxine, and paroxetine [9].
2.4 Somatoform pain
Somatoform pain (SP) is the primary symptom in an ambiguous and unclarified
category called somatization spectrum disorders (SSD), defined as the displaying of
somatic complaints as a result of social stress. It shows a growing incidence (up to
60%) and is a symptom generally unexplained by the medical condition of these
patients (which must be ruled out). The symptomatology—headache and musculo-
skeletal pain—overlaps with other chronic pain syndromes and may be associated
with psychiatric symptoms (depression, anxiety, personality disorders) and thus
makes the diagnosis difficult. The mechanism of this condition is a subject of
debate, but a genetic predisposition plus an altered interpersonal relationship in
childhood and adolescence are the determining factors [10].
Treatment is focused on psychotherapy and modulation of interpersonal rela-
tions, by learning to develop robust, safe, and supportive social relationships.
Besides, acupuncture and massage proved efficacy. Medication includes TADs and
SSRIs [11].
3. Selective serotonin reuptake inhibitors in chronic pain management
Due to the association between chronic pain states and depression and also due
to the continuous need and search for effective analgesic drugs, antidepressants
have long been considered for the treatment of chronic pain. Some antidepressants
are useful in the management of pain syndromes showing analgesic effects, but not
all antidepressants have analgesic properties [12]. TADs are recognized to have
analgesic effects in doses lower than the antidepressant ones. However, frequent
side effects preclude their widespread use.
Consequently, newer generations of antidepressants, like SSRIs and SNRIs, have
been studied in chronic pain management. For SSRIs, efficiency in chronic pain
conditions has been debated, and results are still inconclusive. It is felt that antide-
pressants with both noradrenergic and serotoninergic activities are superior anal-
gesics compared to drugs that possess only serotoninergic activity [13].
Currently available SSRIs are fluoxetine, sertraline, paroxetine, citalopram, and
escitalopram. Fluvoxamine is approved for the treatment of obsessive-compulsive
disorders but has sometimes been used off-label for the treatment of depression. SSRIs
are currently approved and used for the treatment of a wide range of diseases:
depression, anxiety and panic disorders, obsessive-compulsive disorders, post-
traumatic stress disorder, premenstrual dysphoric syndrome, dysthymia, irritable
bowel syndrome, eating disorders, alcohol abuse, and some personality disorders [14].
SSRIs utility for the treatment of chronic pain has been questioned but seems
attractive due to their better side-effect profile compared to first-generation anti-
depressants like TADs, as SSRIs selectively block serotonin reuptake (reabsorption
in the synaptic cleft).
How could SSRIs be useful in chronic pain management? Do they possess both anti-
depressant and intrinsic analgesic properties?
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Even though widely prescribed, the mechanism of action of SSRIs is not yet fully
understood. The traditional theories claim the fact that antidepressant drugs act by
influencing certain brain neurotransmitters [15]. Serotonin (5-HT) is one of the
neurotransmitters which carry signals between neurons. The monoamine signaling
theory of depression explains how SSRIs and other antidepressants work at the
synaptic level by inhibiting the reuptake of one or several neurotransmitters, an
effect which is almost immediate and leads to the increase of the extracellular level
of the mediator. SSRIs are selective inhibitors of the presynaptic 5-HT reuptake
transporter (SERT) that leads to an acute increase in serotonin concentrations in the
synaptic cleft. This effect does not explain why antidepressant drugs work 2–4
weeks after treatment commencement, which might be better explained by recep-
tor downregulation and delayed desensitization of presynaptic serotonin receptors
[16]. Recent findings also suggest changes in brain-derived neurotrophic factor
expression, which might even lead to SSRI antidepressant effect. Another newer
theory suggests that SSRIs impact brain levels of allopregnanolone, enhancing
gamma-amino butyric functions in the brain [14]. Apart from monoamine neuro-
transmitter’s imbalance, the inflammatory theory of depression claims the increased
serum levels of proinflammatory mediators in the depressed patients [17]. As
inflammation is the well-known cause of acute and some type of chronic pain,
proinflammatory mediators play the capital role in initiating nociception and
peripheral sensitization. In vitro experimental studies and early in vivo studies
suggested that SSRIs could inhibit the release of TNF-α, interferon γ, interleukin 1β,
and free radical superoxide [16, 18]. Probably one of the most plausible humoral
links between chronic pain conditions and depression is inflammation. If SSRIs have
intrinsic anti-inflammatory and anti-oxidative properties and could modulate
inflammatory processes, then this could be an explanation for their therapeutic
effect in chronic pain management. The detailed specificity of action for this mech-
anism remains unknown [19]. Intrinsic antihyperalgesic effects in animal models
have recently been described for SSRIs [20–23].
Possible side effects observed during antidepressant treatment with SSRIs also
need to be considered when prescribing SSRIs for chronic pain management.
These side effects include [12, 14, 24]:
• Drowsiness, dry mouth, blurred vision, dizziness
• Gastrointestinal effects: nausea, diarrhea or constipation, vomiting
• Central nervous system effects: insomnia, agitation or restlessness, headache,
tremors, increased sweating, rarely extrapyramidal symptoms, anorexia
• Syndrome of inappropriate antidiuretic hormone secretion with hyponatremia,
somnolence, delirium, confusion
• Sexual dysfunction
• Weight gain
• Platelet dysfunction and increased risk of bleeding
• Drug interactions due to the concomitant hepatic metabolism involving the
cytochrome P450
• Safety issues in pregnancy
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• Serotonin syndrome
Suicide might be a risk occurring early in the treatment, even though larger
epidemiological studies do not confirm this assumption [14].
SSRIs discontinuation syndrome is characterized by sensory and gastrointestinal
symptoms, dizziness, lethargy, and sleep disturbances [25].
3.1 Individual SSRIs and their efficiency in chronic pain conditions as
highlighted in clinical trials
3.1.1 Fluoxetine
Fluoxetine (Prozac™, Sarafem™) has been one of the first SSRIs available
for the treatment of depression. Its use for chronic pain management has been
highlighted in several clinical trials including modest numbers of patients
(Table 1). For chronic tension-type headache, fluoxetine administered in 20 mg
daily dose is equally efficient to desipramine [26]. For the treatment of painful
diabetic neuropathy, fluoxetine is no more effective than placebo and amelio-
rates pain in 48% of the patients, especially the depressed ones [27]. For
somatoform pain disorders, the analgesic effect is related to treatment duration
and is related to its antidepressant effect as depressive patients show greater
improvement compared to non-depressed ones [28]. Fluoxetine was found to
be efficient for the treatment of fibromyalgia when compared to placebo or
amitriptyline [29, 30].
3.1.2 Fluvoxamine
Fluvoxamine (Luvox™) is currently used for the treatment of obsessive-
compulsive disorders, and the therapeutic dose varies widely between 50 and
300 mg. Non-depressed patients with severe chronic tension-type headache
respond to fluvoxamine 50–100 mg daily [31], and it is efficient in central post-
stroke pain, cancer pain, and osteoarthritis [32–34]. However, for chronic can-
cer pain, its beneficial effect has not yet been proven [35].
Study Chronic pain
condition
Dose used for
chronic pain
(mg)
No
patients
Comparator Efficiency
Fluoxetine
10–80 mg/day
for depression
[14]
Walker
et al. [26]
Chronic
tension-type
headache
20 25 Desipramine Equally
efficient
Max et al.
[27]
Diabetic
neuropathy
40 46 Placebo Equally
efficient
Luo et al.
[28]
Somatoform
pain
disorders
20 80 Placebo Efficient for
depressed
patients
Goldenberg
et al. [29]
Fibromyalgia 20 19 Amitriptyline Effective
Arnold et al.
[30]
Fibromyalgia 45  25 60 Placebo Effective
Table 1.
Randomized controlled trials for fluoxetine in chronic pain management.
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3.1.3 Sertraline
Sertraline (Zoloft™) is recommended in single daily doses of 50–200 mg for the
treatment of depression. In small sample size studies, it has proven to be efficient in
non-cardiac chronic chest pain and chronic pelvic pain of prostatic origin in men
[36, 37], but not in women with chronic pelvic pain [38].
3.1.4 Paroxetine
Paroxetine (Paxil™, Seroxat™) is one of the most extensively studied SSRI for
chronic pain management (Table 2). For tension-type daily headache, two studies
failed to prove any beneficial effect [39, 40]. Foster et al. suggested that by
extending treatment periods up to 3–9 months, patients may benefit [41]. For
chronic low back pain, doses of 20 mg are less efficient than maprotiline, and the
effects are similar to placebo [42, 43]. In fibromyalgia, paroxetine improves overall
symptomatology, but the effect on pain is less robust [44]. Paroxetine has been
shown to be useful for the treatment of diabetic peripheral neuropathy, but not
more efficient than imipramine [45]. In a mixed study comparing paroxetine and
citalopram versus gabapentin, the comparable efficiency of these two SSRIs with
gabapentin was shown [46].
Study Chronic pain
condition
Dose
used for
chronic
pain
(mg)
No of
patients
Comparator Efficiency
Paroxetine
10–50 mg
daily for
depression
[14]
Langemark
and Olesen
[39]
Chronic
tension-type
headache
20–30 50 Sulpiride Less efficient
Holroyd et al.
[40]
Chronic
headache,
non-
responding to
amitriptyline
Up to 40 31 Placebo Modest effect
Foster and
Bafaloukos
[41]
Chronic daily
headache
10–50 48 Placebo Efficient when
used for 3–
9 months
Dickens et al.
[42]
Chronic low
back pain
20 91 Placebo Not efficient
Atkinson et al.
[43]
Chronic low
back pain
20 74 Maprotiline Less efficient
Patkar et al.
[44]
Fibromyalgia 12.5–
2.5 mg
116 Placebo Inconclusive
Sindrup et al.
[45]
Diabetic
peripheral
neuropathy
40 29 Placebo and
imipramine
Efficient compared
to placebo, less
efficient compared
to imipramine
Giannopoulos
et al. [52]
Diabetic
peripheral
neuropathy
20–40 101 Citalopram
or
paroxetine
versus
gabapentin
Comparable
efficiency
Table 2.
Randomized controlled trials for paroxetine in chronic pain management.
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3.1.5 Citalopram
Citalopram (Celexa™, Cipramil™) is administered in 10–80 mg dose once daily
for the treatment of depression (Table 3). It has been investigated for the treatment of
fibromyalgia and chronic tension-type headache, with no beneficial results [47–49],
while for somatoform pain disorders it has only moderate analgesic effect [50–52].
3.1.6 Escitalopram
Escitalopram (Cipralex™, Lexapro™) has antidepressive effects in 10–20 mg
daily dose. For chronic low back pain, citalopram has similar results compared to
duloxetine [53]. It has pain-relieving effects in painful diabetic neuropathy and
somatoform disorders [54, 55]. For the treatment of pain symptoms associated with
depression, escitalopram is equally effective with nortriptyline [56].
4. Serotonin norepinephrine reuptake inhibitors in pain management
SNRIs are first-line antidepressants known to inhibit the reuptake of serotonin
and norepinephrine almost exclusively by binding to their transporters (SERT and
NET). This category includes drugs with very different chemical structure and
includes venlafaxine, desvenlafaxine, duloxetine, milnacipran, and
levomilnacipran.
SNRIs show different pharmacokinetics and dynamics and also different affinity
to SERT and NET with consequences on their therapeutic actions (Table 4).
Study Chronic pain
condition
Dose used
for
chronic
pain (mg)
No of
patients
Comparator Efficiency
Citalopram
10–80 mg
for
depression
[14]
Nørregaard
et al. [46]
Fibromyalgia 20–40 43 Placebo No effect
Anderberg
et al. [47]
Fibromyalgia 20–40 40 Placebo Inconclusive
Aragona et al.
[48]
Somatoform pain
disorder
20 35 Reboxetine Moderate
effect
Bendsten
et al. [49]
Chronic tension-
type headache
20 40 Placebo and
amitriptyline
No significant
effect
Viazis et al.
[50]
Gastroesophageal
reflux disease
20 63 Efficient
when
administered
with proton
pump
inhibitors
Roohafza
et al. [51]
Pediatric
functional
abdominal pain
20 86 Placebo Effective
Giannopoulos
et al. [52]
Diabetic
peripheral
neuropathy
20–40 101 Citalopram or
paroxetine
versus
gabapentin
Comparable
efficiency
Table 3.
Randomized controlled trials for citalopram in chronic pain management.
7
Serotonin Reuptake Inhibitors and Their Role in Chronic Pain Management
DOI: http://dx.doi.org/10.5772/intechopen.80711
Side effects of SNRIs are common to all antidepressants, but these drugs add dry
mouth and constipation due to increased levels of noradrenaline. The risk of with-
drawal because of side effects, in patients with chronic pain, was highest for
milnacipran and followed by venlafaxine and duloxetine [57].
4.1 Venlafaxine
Venlafaxine (Effexor™) is an SNRI with mixed action on amine reuptake. When
administrated in low doses, it inhibits SERT and at higher doses NAT. It is indicated
for major depressive disorder (MDD) and also for anxiety, panic disorders, and
social phobia management.
An experimental study showed its antihyperalgesic effect after a single adminis-
tration in a diabetic neuropathic pain model, a result reversed by pretreatment with
yohimbine and chloroamphetamine, but not by naloxone [58].
Long ago, a short case report raised attention to the potential beneficial effect of
venlafaxine in chronic pain management [59], and later others confirmed its bene-
ficial effects in managing neuropathic pain: peripheral neuropathy, postherpetic
neuropathy, headache, and multiple sclerosis. In a systematic review on neuro-
pathic pain, the authors found four trials (high quality evidence): two with positive
results at doses of 150–225 mg venlafaxine ER daily and two with negative results
(lower doses). The number needed to treat (NNT) was 6.4 and the number needed
to harm (NNH) was 11.8 [60].
In elderly patients with low back pain and depression, 150 mg venlafaxine
showed efficacy, but the authors suggested that patients who did not respond to
small doses may benefit from dose augmentation after a 2-week period [61].
Venlafaxine may be useful in the treatment of spinal cord injury (SCI) associ-
ated with MDD because this medication improved SCI-related disability and pain.
Still, further trials are needed to determine optimal doses and efficiency in patients
with SCI without MDD [62, 63].
Studiesinpatientswithtaxane-oxaliplatin-inducedneurotoxicityshowedclinical
improvementaftervenlafaxine(37.5mgbid)[64],andfurtherstudiesareinprogress[65].
Venlafaxine had good results in acute pain; in patients with cancer breast sur-
gery, the preoperative administration of 37.5 mg venlafaxine reduced the postoper-
ative opioid consumption and the incidence of chronic postoperative pain at 6
months [66].
SNRI Bioavailability
(%)
Elimination
half life
Elimination SERT
affinity
NAT
affinity
Active
metabolite
Venlafaxine 45 5 h (IR)
11 h (ER)
Renal High Low Yes
Duloxetine IR 50 12 h Renal + feces High High No
Milnacipran 85 8 h Renal (55%
unchanged)
Moderate Moderate No
Desvenlafaxine 80 11 h (IR)
13–14 h (ER)
Renal (45%
unchanged) at
72 h
High Low No
Levomilnacipran 92 12 h Renal 58%
unchanged
Low High No
SERT, serotonin transporter; NAT, noradrenaline transporter; IR, immediate release; ER, extended release.
Table 4.
SNRIs pharmacokinetics and pharmacodynamics.
8
Serotonin
A former Cochrane meta-analysis reported little evidence to support the recom-
mendation of venlafaxine in neuropathic pain management and noted that venlafaxine
promoted fatigue, nausea, dizziness, and somnolence with a low incidence [67].
Eventually, two recent reviews (11 and 13 trials) found that venlafaxine was bene-
ficial in neuropathic pain management with good tolerability claiming the necessity for
further research to expand these findings [68, 69]. There are contradictory findings in
these recent reviews, but there is need for further good quality evidence.
4.2 Desvenlafaxine
Desvenlafaxine (Pristiq™) is the third SNRI with FDA approval and only
indication for MDD management (50–400 mg daily). The daily recommended
dose is 50 mg. Desvenlafaxine is the salt of an active metabolite of venlafaxine,
and the ER form allows 1 day administration. It presents a good bioavailability
(Table 4) and shows a low binding to plasma proteins (30%). Desvenlafaxine
binds to SERT 10 times more than to NAT and also has a weak affinity for
dopamine transporter. Adverse effects are dose-dependent and typical to all anti-
depressants. Doses of 200–400 mg showed efficacy in DPN management, with
effect sizes similar to duloxetine [70] and with increased side effects at higher
doses. At the moment, there is a lack of evidence to support the use of
desvenlafaxine in chronic pain management.
4.3 Duloxetine
Duloxetine (Cymbalta™; DLX) is probably the most used drug from this
class of antidepressants. Aside from MDD and urinary incontinence, duloxetine
is indicated for anxiety disorder, chronic pain in diabetic neuropathy, fibromy-
algia, musculoskeletal pain, and osteoarthritis. DLX is a potent SNRI, with a
high affinity for both SERT and NAT. It has a moderate bioavailability, with an
elimination half-time of 12 h. It is metabolized in the liver and does not possess
any active metabolite. Duloxetine exerts antihyperalgesic and allodynic effects,
by impairing nociception at a peripheral level (blocks NaV 1.7 current) and by
inhibiting neuronal firing [71]. With acute administration, DLX leads to ele-
vated levels of NA and 5-HT, and with chronic treatment, it does not affect
further basal levels of these monoamines [72]. Even if the significant pain-
relieving effect was found after 7 weeks of treatment [73], others showed that
patients treated with DLX for OA knee pain or low lumbar pain who have <10%
reduction in pain after 4 weeks treatment have low chance to reach moderate
pain reduction by the end of 12 weeks [74]. DLX’s recommended dose for the
first week is 30 mg, raising the dose to 60 mg in the second week in order to
avoid a high incidence of side effects.
Because of interfering with platelet function, it is indicated to stop its adminis-
tration 4 days before surgery.
Data from animal pain models and clinical studies on DLX administration in
perioperative setting (spine, knee, breast surgery) suggested its analgesic
effects. Pre- and postoperative duloxetine reduced 24-h opioid consumption,
delayed first analgesic requirement, and reduced incidence of chronic postoper-
ative pain at 6 months, being of primary interest for patients with preoperative
chronic pain and spine surgery [75–77]; results from ongoing studies will
respond to questions remained unanswered. Duloxetine shows good tolerability
with dizziness and nausea, dry mouth, and constipation, as more frequent side
effects [78].
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While duloxetine proved its efficacy in chronic nociceptive/neuropathic pain
[79–83] (Table 5), it is yet unrevealed its possible impact on acute postoperative
pain and chronic postoperative pain.
4.4 Milnacipran
Milnacipran (Savella™) described in 1998 by Briley as a potent SNRI that
showed similar inhibition on both monoamine re-uptakes, in vitro and in vivo,
was approved in Europe for the treatment of depression. It did not link to alpha
adrenoreceptors, muscarinic cholinergic, and histaminic receptors and showed
no effect on beta-adrenergic receptors sensitivity, thus having reduced side
effects. The drug has an excellent bioavailability with a mean peak plasma
concentration reached between 0.5 and 4 h after the oral administration. About
13% binds to plasma proteins and is wholly eliminated after 36 h [84]. Studies
on the efficacy of milnacipran in psychiatric patients revealed its significant
superiority when compared to SSRIs. Most frequent adverse effects were nau-
sea, dry mouth, and headaches [85]. Milnacipran has FDA approval for the
management of fibromyalgia.
In 2006, Obata et al. found that intrathecal administration of milnacipran
reduced allodynia in a rat neuropathic pain model [86].
Other experimental data confirmed these findings regarding milnacipran’s
antiallodynic and antihyperalgesic effects [87] and showed its effectiveness in
treating allodynia in vincristine-induced neuropathic pain [88].
In a Cochrane meta-analysis, Cording et al. analyzed six studies (4238 patients)
that compared milnacipran 100/200 mg with placebo in fibromyalgia. By using a
“conservative”method of analysis, they found 26% positive response with
milnacipran as compared to 19% for placebo and an increased rate of side effects [89].
Despite the evidence that milnacipran (100 or 200 mg) was found to be useful in
neuropathic pain, as compared with placebo, Derry et al.’s meta-analysis did not
Study Pathology No trials Number of
patients
Findings
Lunn et al.
[79]
60 mg
Diabetes
fibromyalgia
14
8-DPN; 6-
FM
6407 In both category showed efficacy
DPN-NNT 5
FM-NNT 8
Quilici et al.
[80]
Diabetes 11 679 Effective in DPN
NNT = 5
Good toleration
Superior to placebo
Discontinuation due to AE
Wang et al.
[81]
60/120 mg
(QD)
Knee
osteoarthritis
3 1011 Significant pain reduction
Improved function
Reported “acceptable” AE
Lee and Song
[82]
Fibromyalgia 9 5140 Results showed equal efficacy and
tolerability
Hauser et al.
[83]
Fibromyalgia 10 6038 Small benefit over placebo
QD, quaque die; DLX, duloxetine; MLC, milnacipran; DPN, diabetes polyneuropathy; NNT, number needed to
treat; FM, fibromyalgia; AE, adverse effect.
Table 5.
Meta-analysis for duloxetine in chronic pain management.
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obtain enough data to confirm former data and support its recommendation in
chronic neuropathic pain [90]. Future trials are needed to establish milnacipran’s
possible favorable effects in pain management.
4.5 Levomilnacipran
Levomilnacipran (Fetzima™) is the enantiomer ofmilnacipranwith the highest
activity, and its primary indication isMDD.Atusual doses, this drug is known topossess
a higher potency for norepinephrine (twofold) reuptake inhibition, as comparedwith 5-
HT [91]; butwith higher doses, it showed equal efficacy in increasing 5-HT andNE
levels [92].
Regarding tolerability, the most frequently recorded adverse effects were nau-
sea, constipation, and sweating, although a small proportion (3–6%) of patients
recorded increased blood pressure and heart rate [93]. We have not found any data
regarding its use in chronic pain patients.
5. Double function serotonin reuptake inhibitors
A particular category of drugs includes SRIs with double mechanism: 5-HT
reuptake inhibition and interaction with 5-HT receptors. Animal studies have
suggested that these receptors are included in the descending pain inhibitory sys-
tems [94, 95], and their activation is involved in reducing the acute nociceptive and
neuropathic pain [96].
5.1 Trazodone
Trazodone (Desyrel™, Oleptro™) is the first non-tricyclic antidepressant
approved for the treatment of MDD (1981), and it is also used to treat anxiety,
alcohol dependence, insomnia, and chronic pain (off-label). It was developed for
the treatment of “mental pain,”which was recognized to occur in depression [97]. It
acts as a SRI, antagonist of 5-HTA2 receptor, and a partial agonist for 5-HTA1
receptors. Secondary acts as an antagonist to α1-adrenergic receptors and lacks any
effect on cholinergic receptors. The drug shows a 65% oral bioavailability, 90%
plasma protein binding capacity, and is metabolized in the liver (via CYP3A4) to an
active metabolite—mCPP. The main excretion route is renal, and the biological
half-time is 7 h. Side effects are not only shared with the other antidepressants but
also list dry mouth, orthostatic hypotension, cardiac arrhythmias, and priapism.
Trazodone showed some efficacy in several chronic pain conditions represented
in Table 6, but future studies are needed.
5.2 Nefazodone
Nefazodone (Serzone™) is related to trazodone but with fewer side effects. Doses
of 300–600 mg are indicated for the treatment of MDD, panic disorders, and aggres-
sive behavior. It acts as an antagonist of 5-HTA2 and 5-HTC2 receptors and serotonin,
norepinephrine, and dopamine reuptake inhibitor. Its effects on the mentioned
receptors enhance neurotransmission by an increased binding on the 5-HTA1 recep-
tors. Nefazodone shows an affinity for α1 and less for β-adrenoreceptors and does not
interact with muscarinic cholinergic receptors. It has low bioavailability; it is metab-
olized in the liver (CYP3A4) and has four metabolites (mCPP active). Nefazodone
has a biological half-time between 2 and 4 h and is excreted in urine. Frequent side
effects are dry mouth, dizziness, and sleepiness, and rare, severe liver damage [98].
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Murine studies yielded the capacity of nefazodone to potentiate opioid analgesia
by acting through μ1 and μ2 receptors without affecting mortality [99]. Other results
indicated that rats treated with nefazodone have shown an increased expression of
μ-opioid receptors in the area of the central nervous system related to pain percep-
tion and modulation [100].
Even if it shows an excellent clinical profile, at this time we found only
a two-center open-label study on the efficacy of nefazodone on
preventing chronic daily headache. The study included 52 patients
who received nefazodone between 100 and 450 mg (300 mg median) for
12 weeks. The results showed significantly lower incidence and intensity of
daily headache and a good tolerance for nefazodone [101].
5.3 Vilazodone
Vilazodone (Viibryd™) approved by FDA (2011) for the treatment of MDD is a
partial agonist to the 5-HTA1 receptor, GABA agonist, and SRI. Currently is pre-
sumed that it increases serotoninergic neurotransmission and it shows fast onset
and good effect at daily doses between 10 and 40 mg. Vilazodone has 72% bioavail-
ability when it is taken with food, is metabolized in the liver (via CYP3A4), and it
did not possess active metabolites. It is excreted in urine and feces and has a
biological half-time of 25 h [102]. Side effects include nausea, vomiting, diarrhea,
and insomnia (>5%). Sexual adverse reactions and low influence on weight-gain
were reported [103]. Even if it presumed that vilazodone should add value in the
treatment of patients with the depression-pain syndrome, there are not yet available
data on its efficacy in pain states.
Study Chronic pain
condition
Dose Number
of
patients
Comparator Efficiency
Wilson
[103]
Diabetic
neuropathy
50–100 mg 31 — Effective
Ventafridda
et al. [104]
Deafferentation
pain
— 45 Amitriptyline Equal efficacy
Goodkin
et al. [105]
Chronic low back
pain
201 mg (average) 42 Placebo Similar effect
Morillas-
Arques et al.
[106]
Fibromyalgia 50–300 mg 66 — Effective
Calandre
et al. [107]
Fibromyalgia 50–300 mg
trazodone + 75–
450 mg
pregabalin
41 — Pregabalin enhanced
the favorable effects
of trazodone
Davidoff
et al. [108]
Dysesthetic pain
following spinal
cord injury
150 mg 18 placebo Similar effect
Battistella
et al. [109]
Migraine
(pediatric 7–
18 years)
1 mg/kg 40 placebo Effective
Frank et al.
[110]
Rheumatoid
arthritis
1.5 mg/kg 47 — No effect
Table 6.
Trials for trazodone in chronic pain management.
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6. Conclusions
SSRIs seem to be effective in most chronic pain conditions, and they are well
tolerated [41]. The efficacy of SSRIs might be comparable to TADs and SNRIs, but
their tolerability and safety are superior [30]. For some chronic pain conditions,
valuable, while for others their utility is limited:
• For migraine, SSRIs are not better than placebo for reducing the number of
attacks, and results of studies on migraine are conflicting [24, 111].
• Patients with chronic tension-type headache seem to benefit from SSRIs [24].
• There are conflicting results regarding the use of SSRIs for pelvic pain.
• Non-cardiac chest pain might benefit from SSRIs.
• Low back pain does not seem to respond well to SSRIs.
• The effects of SSRIs on fibromyalgia are uncertain [112].
• Diabetic neuropathy looks to improve from SSRIs treatment.
• Post stroke central pain might improve with fluvoxamine.
• Evidences support that antidepressants are useful for the treatment of irritable
bowel syndrome [113].
• There is no evidence from randomized controlled trials to recommend
antidepressants to treat chronic non-cancer pain in children and adolescents
[114] or adults.
Even though several clinical trials were published, the results remain inconclu-
sive. That happens because the sample sizes are quite modest rendering the studies
slightly underpowered. Primary outcomes are variable: self-reported pain scores,
effect on pain symptoms observed by the physician, complex pain questionnaires,
and effects on quality of life and functionality. Current drug classes available for
chronic pain treatment include anti-inflammatory drugs, opioids, gabapentinoids
along with interventional or surgical management, and physical activity. Heteroge-
neity of the chronic pain syndromes, many currently available drugs and treatment
modalities, and drug-drug and drug-interventional management associations
should be considered when designing future larger scale trials.
In conclusion, compared to all other antidepressants in the management of
chronic pain, for SSRIs, the data are still inconclusive, and studies are fewer in
number. For depression, SSRIs are considered first-line agents due to a favorable
side-effect profile and good tolerability. However, they have not yet entered first-
line use for neuropathic pain conditions [12]. Probably, it would be advisable to
restrict their use for those patients failing to respond to other medications or who do
not tolerate side effects.
From SNRIs category, in particular duloxetine is already a first-line treatment
for DPN and other chronic pain syndromes (fibromyalgia, musculoskeletal pain,
and osteoarthritis), showing good results and an acceptable safety profile. It also
showed favorable effects on chronic postoperative pain and life quality with the
perioperative administration in surgery with a high incidence of chronic pain
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(spine, breast). Venlafaxine is a drug of choice for the treatment of fibromyalgia.
Milnacipran proved antiallodynic and antihyperalgesic effects and might show fur-
ther positive results in chronic pain management; well-designed trials are still
required.
SRIs seem to play their role through the spinal modulation pain pathways being
less involved in reducing nociception, and that is probably why their effects are
more evident in patients with chronic pain states.
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